ArticleCancers2021
Proteomic Analyses of Fibroblast- and Serum-Derived Exosomes Identify QSOX1 as a Marker for Non-invasive Detection of Colorectal Cancer.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Extracellular vesicle biomarkers in circulation for colorectal cancer detection: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Phosphorylation beyond the plasma membrane: How secretory pathway kinases sculpt the cellular dialogue in cancer (Review).International journal of molecular medicine · 2026Review
- Nanomaterial-based total analysis systems for isolation and detection of exosomal biomarkers in cancer diagnosis.Materials today. Bio · 2026Review
- Role of cancer-associated fibroblast-derived exosomes in pancreatic cancer: clinical therapeutic potential and targeting challenges.Frontiers in immunology · 2026Review
- Stromal QSOX1 loss is a distinctive feature of colorectal cancer and correlates with tumor expansion.Histochemistry and cell biology · 2025Article
- Extracellular vesicles in colorectal cancer.Annals of coloproctology · 2025Review
- Personalized human umbilical cord mesenchymal stem cell-derived exosome pre-treatment based on the simulation of scar microenvironment characteristics: a promising approach for early scar treatment.Molecular biology reports · 2025Article
- Quantifying extracellular vesicle heterogeneity: the effect of process conditions on protein cargo for skin therapy.Stem cell research & therapy · 2025Review
- Recent Progress in Developing Extracellular Vesicles as Nanovehicles to Deliver Carbohydrate-Based Therapeutics and Vaccines.Vaccines · 2025Review
- Proteomic and functional analysis of alpaca (Frontiers in veterinary science · 2025Article
- Relationship between exosomes and cancer: formation, diagnosis, and treatment.International journal of biological sciences · 2025Review
- Liquid biopsy in cancer current: status, challenges and future prospects.Signal transduction and targeted therapy · 2024Review
- Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy.Signal transduction and targeted therapy · 2024Review
- Mitoferrin2 is a synthetic lethal target for chromosome 8p deleted cancers.Genome medicine · 2024Article
- The multifaceted role of extracellular vesicles (EVs) in colorectal cancer: metastasis, immune suppression, therapy resistance, and autophagy crosstalk.Journal of translational medicine · 2024Review
- Effects of redox modulation on quiescin/sulfhydryl oxidase activity of melanoma cells.Molecular and cellular biochemistry · 2024Article
- Decreased NSD2 impairs stromal cell proliferation in human endometrium via reprogramming H3K36me2.Reproduction (Cambridge, England) · 2024Article
- Enhanced secretion of promyogenic exosomes by quiescent muscle cells.Frontiers in cell and developmental biology · 2024Article
- Identification of Diagnosis and Typological Characteristics Associated with Ferroptosis for Ulcerative ColitisEndocrine, metabolic & immune disorders drug targets · 2024Article
- Development of tandem antigen capture ELISAs measuring QSOX1 isoforms in plasma and serum.Free radical biology & medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The treatment of colorectal cancer (CRC) has improved during the last decades, but methods for crucial early diagnosis are yet to be developed. The influence of the tumour microenvironment on liquid biopsies for early cancer diagnostics are gaining growing interest, especially with emphasis on exosomes (EXO), a subgroup of extracellular vesicles (EVs). In this study, we established paired cancer-associated (CAFs) and normal fibroblasts (NF) from 13 CRC patients and investigated activation status-related protein abundance in derived EXOs. Immunohistochemical staining of matched patient tissue was performed and an independent test cohort of CRC patient plasma-derived EXOs was assessed by ELISA. A total of 11 differentially abundant EV proteins were identified between NFs and CAFs. In plasma EXOs, the CAF-EXO enriched protein EDIL3 was elevated, while the NF-EXO enriched protein QSOX1 was diminished compared to whole plasma. Both markers were significantly reduced in patient-matched CRC tissue compared to healthy colon tissue. In an independent test cohort, a significantly reduced protein abundance of QSOX1 was observed in plasma EXOs from CRC patients compared to controls and diagnostic ROC curve analysis revealed an AUC of 0.904. In conclusion, EXO-associated QSOX1 is a promising novel marker for early diagnosis and non-invasive risk stratification in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.